Yerim Said Ali, Khazraji Youssef Chami, Bekkali Rachid, Bennai Maria, Bahra Nassiba, Chaoui Imane, Chellat Fatima Zahra, Gaizi Zineb, Tachfouti Nabil, Benabdellah Anas, Belkadi Bouchra, Attaleb Mohammed, Berraho Mohamed Amine, El Mzibri Mohammed
Biology and Medical Research Unit, Centre National de L'Energie, des Sciences et Techniques Nucléaires (CNESTEN), Rabat, Morocco; Microbiology and Molecular Biology Laboratory, Faculty of Sciences, Mohammed V University, in Rabat, Morocco.
Fondation Lalla Salma- Prévention et Traitement des Cancers, Rabat, Morocco.
Tumour Virus Res. 2025 Apr 17;19:200318. doi: 10.1016/j.tvr.2025.200318.
Recently, the World Health Organization recommended integrating HPV testing into cervical cancer screening programs globally. This study aimed to compare the GeneXpert assay with PCR-sequencing for HPV detection and genotyping to assess the feasibility of incorporating HPV molecular testing into cervical cancer screening. A total of 1000 women aged 30 or 40 from rural and urban areas across four regions in Morocco with high sexually transmitted infection prevalence were recruited. After excluding 21 invalid tests, DNA testing on the remaining 979 samples showed an HPV prevalence of 4.0 % (39/979) by PCR and 5.0 % (49/979) by Xpert, with an overall prevalence of 5.7 % (56/979) when combining both techniques. The concordance rate between the tests was 97.5 %. Notably, the Xpert HPV assay was highly efficient in detecting HPV, with nearly all identified HPVs being high-risk oncogenic types, predominantly HPV16, 18, 31, 35, and 45. The Xpert HPV assay has demonstrated excellent analytical performance, making it a reliable option for HPV detection in vaginal and cervical swabs. Its integration into primary cervical cancer screening programs could significantly enhance the early detection of HPV-positive cases, thereby strengthening the screening framework and potentially reducing both the incidence and mortality of cervical cancer. Future studies should focus on confirming these results and exploring the utility of this method in conjunction with other diagnostic tools such as visual inspection with acetic acid (VIA) for a comprehensive assessment of its effectiveness in real-world settings.
最近，世界卫生组织建议在全球范围内将人乳头瘤病毒（HPV）检测纳入宫颈癌筛查项目。本研究旨在比较GeneXpert检测法与聚合酶链反应测序法（PCR测序）在HPV检测和基因分型方面的效果，以评估将HPV分子检测纳入宫颈癌筛查的可行性。在摩洛哥四个性传播感染率较高地区的城乡，共招募了1000名年龄在30岁或40岁的女性。排除21份无效检测后，对其余979份样本进行DNA检测，结果显示PCR检测的HPV感染率为4.0%（39/979），GeneXpert检测的感染率为5.0%（49/979），两种技术联合检测的总体感染率为5.7%（56/979）。两种检测方法的一致性率为97.5%。值得注意的是，GeneXpert HPV检测法在检测HPV方面效率很高，几乎所有检测出的HPV都是高危致癌类型，主要是HPV16、18、31、35和45。GeneXpert HPV检测法已显示出出色的分析性能，使其成为阴道和宫颈拭子中HPV检测的可靠选择。将其纳入原发性宫颈癌筛查项目可显著提高HPV阳性病例的早期检测率，从而加强筛查框架，并有可能降低宫颈癌的发病率和死亡率。未来的研究应着重于证实这些结果，并探索该方法与其他诊断工具（如醋酸目视检查法（VIA））联合使用的效用，以便在实际环境中对其有效性进行全面评估。
